Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Glatiramer Acetate in Clinically Isolated Syndrome (PreCISe)
NCT00666224Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2004
- Primary completion
- Oct 2007
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in clinically isolated syndrome (CIS) comparing Glatiramer acetate with Placebo (2 arms). Primary endpoints: Time to Clinically Definite Multiple Sclerosis Conversion up to 3 years and Twenty-fifth Percentile Kaplan-Meier Estimates for Time From Randomization to Conversion to Clinically Definite Multiple Sclerosis up to 3 years. Started Jan 2004; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT00666224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00666224.